Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Year: 2022
Type: article
Source: Blood
Authors: Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein
Institutions: Research Medical Center, University of Colorado Anschutz, Colorado Blood Cancer Institute, Presbyterian St. Luke's Medical Center, Institut Gustave Roussy, Fondation Gustave Roussy, Centre Hospitalier Universitaire de Bordeaux, Atlantic Health System, City Of Hope National Medical Center, The University of Texas MD Anderson Cancer Center, Centre Hospitalier Universitaire de Nice, University of California, Los Angeles, Syros Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310127720